Aprotinin® diminishes inflammatory processes

International Journal of Cardiology

Volumn 53, Issue SUPPL., 1996, Pages

  Soeparwata, Rasjid ^a,c   Hartman, Alan R ^b   Frerichmann, Uwe ^a   Stefano, George B ^b   Scheld, Hans H ^a   Bilfinger, Thomas V ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b STONY BROOK UNIVERSITY   (United States)

^c NONE   (Germany)

Author keywords

Aprotinin ; CABG; CPB; Inflammatory cytokine

Indexed keywords

APROTININ; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; HEMOSTATIC AGENT; SERINE PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART INFARCTION; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; MALE; PRIORITY JOURNAL; ACUTE PHASE RESPONSE; BLOOD; CORONARY ARTERY BYPASS GRAFT; DOWN REGULATION; DRUG EFFECT; GRANULOCYTE; IMMUNOLOGY; MACROPHAGE; MIDDLE AGED;

ACUTE-PHASE REACTION; APROTININ; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; CYTOKINES; DOWN-REGULATION; FEMALE; GRANULOCYTES; HEMOSTATICS; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; SERINE PROTEINASE INHIBITORS;

EID: 0030602492     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-5273(96)02573-9     Document Type: Article

References (49)

1. Edmunds LH. Why cardiopulmonary bypass makes patients sick: Strategies to control the blood synthetic surface interface. Adv Cardiac Surg 1995; 6: 131-167.
2. Pannen HJ, Robothaun JL. The acute phase response. New Horiz 1995; 3: 183-197.
3. Bilfinger TV, Fricchione G, Stefano GB. Neuroimmune implications of cardiopulmonary bypass. Adv Neuroimmunol 1993; 3: 277-288.
4. Stefano GB, Bilfinger TV. Human neutrophil and macrophage chemokinesis induced by cardiopulmonary bypass: Loss of DAME and IL-1 chemotaxis. J Neuroimmunol 1993; 47: 189-198.
5. Stefano GB, Kushnerick V, Rodriguez M, Bilfinger TV. Inhibiting effect of morphine on granulocyte stimulation by tumor necrosis factor and substance P. Int J Immunopharmacol 1994; 16: 329-334.
6. Stefano GB, Rodriguez M, Glass R, Cesases F, Hughes TK, Bilfinger TV. Hyperstimulation of leukocytes by plasma from cardiopulmonary bypass patients is diminished by morphine and IL-10 pretreatment. J Cardiovasc Surg 1995; 36: 25-30.
7. Boyum A. Separation of lymphocytes; granulocytes and monocytes from human blood using iodinated density gradient media. Methods Enzymol 1984; 108: 88-103.
8. Hugh TK, Smith EM, Cadet P, Sinisterra J, Leung MK, Scharrer B, Stefano GB. Interaction of immunoactive monokines (IL-1 and TNF) in the bivalve mollusc mytilus edulis. Proc Natl Acad Sci 1990; 87: 4426-4429.
9. Stefano GB, Paemen LR, Hughes TK. Autoimmunoregulation: differential modulation of CD1O/neutral endopeptidase 24.11 by tumor necrosis factor and neuropeptides. J Neuroimmunol 1992; 41: 9-14.
10. Schon JC, Torre Bueno J, Stefano GB. Microscopic computer-assisted analysis of conformational state: reference to neuroimmunology. Adv Neuroimmunol 1991; 1: 252-259.
11. Blackstone EH, Kirklin JW, Stewart RW, Chenoweth DE. The damaging effects of cardiopulmonary bypass. In: Wu KK, Rossi EC, editors. Prostaglandins in Clinical Medicine. Cardiovascular and Thrombotic Disorders, Chicago, Year Book Medical, 1982; 355-369.
12. Downing SW, Edmunds LH. Release of vasoactive substances during cardiopulmonary bypass. Ann Thoracic Surg 1992; 54: 1336-1343.
13. Martinez Pallns AE, Merluo P, Bru M, Conejero R et al. Can selective digestive decontamination avoid the endotoxemia and cytokine activation promoted by cardiopulmonary bypass. Crit Care Med 1993; 21 Suppl 11: 1684-1691.
14. Jansen PG, Te Velthuis H, Ordemans Van Straaten MM et al. Perfusion related factors of endotoxin release during cardiopulmonary bypass. Eur J Cardiothoracic Surg 1994; 8 Suppl 3: 125-129.
15. Mirther M, Simoni J, Dickson M. Elevated levels of endotoxin, oxygen derived free radicals and cytokines during extracorporeal membrane oxygenation. J Pediatr Surg 1992; 27 Suppl 9: 1199-1202.
16. Ratlif NB, Young WG, Hackel D et al. Pulmonary injury secondary to extracorporeal circulation; an ultrastructural study. J Thoracic Cardiovasc Surg 1973; 65: 425-432.
17. Abel RM, Buckley MJ, Austen WG et al. Etiology, incidence and prognosis of renal failure following cardiac operations: results of a prospective analysis of 500 consecutive patients. J Thoracic Cardiovasc Surg 1976; 71: 32-42.
18. Fernandez-del Castillo C, Harringes W, Warshaw AL et al. Risk factors for pancreatic cellular injury after cardiopulmonary bypass. New Engl J Med 1991; 325: 382-387.
19. Shaw PJ, Bates D, Aartidge NEF et al. Neurologic and neuropsychological morbidity following major surgery; comparison of coronary artery bypass and peripheral vascular surgery. Stroke 1987; 18: 700-707.
20. Michie MR, Wilmore DW. Sepsis, signals, and surgical sequelae. Arch Surg 1990; 125: 531-536.
21. Shapiro L, Gelfand JA. Cytokines and sepsis pathophysiology and therapy. New Horiz 1993; 1: 13-22.
22. Lowry SF. Anti-cytokine therapies in sepsis. New Horiz 1993; 1: 120-126.
23. Trady KJ, Foug J, Hesse DG et al. Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987; 330: 662-665.
24. Mehnein HA, Ebba H, Rodriguez JL et al. Relationship of the pro-inflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thoracic Cardiovasc Surg 1994; 108: 626-635.
25. Fiering B, Philip I, Rolland C et al. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass. J Cardiovasc Surg 1994; 108: 636-641.
26. Butler J, Chong GL, Baigne RJ et al. Cytokine responses to cardiopulmonary bypass with membrane and bubble oxygenation. Ann Thoracic Surg 1992; 53: 833-888.
27. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement level in patients undergoing cardiopulmonary bypass. J Thoracic Cardiovasc Surg 1993; 106: 1008-1016.
28. Finn A, Naik S, Klein N et al. Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass. J Thoracic Cardiovasc Surg 1993; 105: 234-241.
29. Whitten C, Latson T, Allison P et al. Does aprotinin inhibit cardiopulmonary bypass induced inflammation? Anesthesiology 1992; 177: A266.
30. Sekido N, Mukaido N, Harada A, Nakanishi I, Watanabe Y, Matsushima K. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 1993; 365: 654-657.
31. Fukata J, Usui T, Naitoh Y, Nakai Y, Imura H. Effects of recombinant human interleukin-1 alpha-1 beta-2 and -6 on ACTH synthesis and release in the mouse pituitary tumor cell line AIT-20. J Endocrinol 1989; 122: 33-39.
32. Makman MH, Bilfinger TV, Stefano GB. Human granulocytes contain an opiate alkaloid-selective receptor mediating inhibition of cytokine induced activation and chemotaxis. J Immunol 1995; 154: 1323-1330.
33. Metinko AP, Kunkel SL, Standiford J, Strieter RM. Anoxia-hyperoxia induces monocyte-derived interleukin-8. J Clin Invest 1992; 90: 791-798.
34. Rot A. Some aspects of NAP-1 pathophysiology: lung damage caused by a blood borne cytokines. In: Westwick J, editor. Chemotactic Cytokines, New York 1991; Plenum Press, 127-135.
35. Jansen NJ, van Oeveren W, Gu YJ, van Vliet MH, Eijsman L, Wildevuur CR. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thoracic Surg 1992; 54: 744-748.
36. Laidler J, Paes ML, Wheeler J, Freeman R, Robertson H. Detection of circulating tumor necrosis factor αafter elective cardiopulmonary bypass. Perfusion 1991; 6: 51-54.
37. Markewitz A, Faist E, Lang S, Endres S, Hultner L, Reichart B. Regulation of acute phase response after cardiopulmonary bypass by immunomodulation. Ann Thoracic Surg 1993; 55: 389-394.
38. Markewitz A, Faist E, Lang S, Endres S, Fucks D, Reichart B. Successful restoration of cell-mediated immune response after cardiopulmonary bypass by immunomodulation. J Thoracic Cardiovasc Surg 1993; 105: 15-24.
39. Bentler B, Krochin N, Milsask IW et al. Control of cachectin (tumor necrosis factor) synthesis: mechanism of endotoxin resistance. Science 1986; 232: 977-982.
40. Dower SK, Birel TA, Sims JE. Interleukin-1. Adv in Neuroimmunol 1992; 2: 1-16.
41. Bilfinger TV, Stefano GB. Evidence of an immunocyte activation molecule(s) in plasma of patients undergoing cardiopulmonary bypass. J Cardiovasc Surg 1993; 34: 129-133.
42. Faymonville ME, Pincemail J, Duchateau J et al. Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans. J Thoracic Cardiovasc Surg 1991; 102: 309-317.
43. Summers ST, Wyatt LE, Freischlag JA. Persistent neutrophil (PMN) activation 24 h after ischemia and reperfusion. J Surg Res 1994; 56: 130-133.
44. Freischlag JA, Hanna D. Persistent neutrophil (PMN) phagocytosis and chemotaxis after reperfusion injury. J Surg Res 1992; 52: 152-156.
45. Elgebaly SA, Hashamsi FH, Houser SL, Allam ME, Doyle K. Cardiac derived neutrophil chemotactic factors: detection in coronary sinus effluents in patients undergoing myocardial revascularization. J Thoracic Cardiovasc Surg 1992; 103: 952-959.
46. Kawrata H, Sawatari K, Mayer JE. Evidence for the role of neutrophils in reperfusion injury after cold cardioplegia ischemia in neonatal lambs. J Thoracic Cardiovasc Surg 1992; 103: 908-918.
47. Lord RA, Roath S, Thompson JF, Chanit AB, Francis JL. Effect of Aprotinin on neutrophil function after major vascular surgery. Br J Surg 1992; 79: 517-521.
48. Hallett MB, Shandell A, Young HL. Mechanism of protection against "reperfusion injury" by Aprotinin: roles of polymorphonuclear leukocytes and oxygen radicals. Biochem Pharmacol 1985; 34: 1757-1761.
49. Hartmann JR, Robinson JA, Gunnar RM. Chemotactic activity in the coronary sinus after experimental myocardial infarction: effects of pharmacologic interventions of ischemic injury. Am J Cardiol 1977; 40: 550-555.